| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 805.6 | 813.56 | 831.81 | 571 |
yoy growth (%) | -0.97 | -2.19 | 45.67 | 5.01 |
Raw materials | -311.96 | -294.95 | -305.23 | -181.09 |
As % of sales | 38.72 | 36.25 | 36.69 | 31.71 |
Employee costs | -230.21 | -219.54 | -216.7 | -153.53 |
As % of sales | 28.57 | 26.98 | 26.05 | 26.88 |
Other costs | -177.25 | -163.6 | -189.18 | -190.09 |
As % of sales (Other Cost) | 22 | 20.1 | 22.74 | 33.29 |
Operating profit | 86.18 | 135.47 | 120.7 | 46.29 |
OPM | 10.69 | 16.65 | 14.51 | 8.1 |
Depreciation | -16.95 | -20.13 | -18.58 | -14.74 |
Interest expense | -0.95 | -1.09 | -1.14 | 0 |
Other income | 14.76 | 12.84 | 12.99 | 12.25 |
Profit before tax | 83.04 | 127.09 | 113.97 | 43.8 |
Taxes | -21.44 | -33.79 | -41.76 | -17.89 |
Tax rate | -25.81 | -26.58 | -36.64 | -40.84 |
Minorities and other | 0 | 0 | 0 | 0 |
Adj. profit | 61.6 | 93.3 | 72.2 | 25.91 |
Exceptional items | 0 | 0 | 0 | 0 |
Net profit | 61.6 | 93.3 | 72.21 | 25.91 |
yoy growth (%) | -33.97 | 29.2 | 178.69 | 29.22 |
NPM | 7.64 | 11.46 | 8.68 | 4.53 |
It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.
This combination drug is used to treat chronic obstructive pulmonary disease (COPD) in adults, relieving symptoms and preventing exacerbations.
For the first half (H1) of FY25, the revenue rose to ₹795.5 Crore, driven by growth in oncology, biopharmaceuticals, and rare disease segments.
The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.
The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.
Here are some of the stocks that may see significant price movement today: Punjab National Bank, NTPC, Power Grid, etc.
The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
